Clarity begins trial for pediatric neuroblastoma therapy

2020 07 23 21 58 4280 Cancer Radiotherapy 400

Radiopharmaceutical firm Clarity Pharmaceuticals has begun recruitment for a phase I/IIA clinical trial evaluating its SARTATE peptide receptor radionuclide therapy for pediatric patients with neuroblastoma.

The open label, dose-escalation trial will administer Cu-67 SARTATE to pediatric patients with high-risk neuroblastoma at Memorial Sloan Kettering Cancer Center in New York.

Neuroblastoma is the most common type of cancer to be diagnosed in children under the age of 1 and accounts for 15% of pediatric cancer deaths. The five-year survival rate for children with high-risk neuroblastoma is only 40%-50%, the researchers noted.

Page 1 of 435
Next Page